Status: Recruiting
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
This study is one single group of participants with advanced solid tumors. It is the first time the drug has been used in humans. There will be two parts including Dose Escalation and Dose Expansion to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FZ-AD004.
Participants needed: 121
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.Updated: Jan 22, 2026Locations: 1
Eligibility criteria
Patients able to give written informed consent; [+6]
Have had other malignant tumors in the past 5 years; [+6]